Login to Your Account

Wilex’s Heidelberg Pharma in First ADC Deal with Roche

By Cormac Sheridan
Staff Writer

Wednesday, September 4, 2013
MUNICH, Germany – Shares in Wilex AG gained as much as 12 percent Monday on news that its subsidiary, Heidelberg Pharma GmbH, entered a research collaboration and option agreement with Roche Holding AG, based on its preclinical antibody-drug conjugate (ADC) technology.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription